European ScreeningPort and Merck KGaA Sign Research Agreement

29-Oct-2010 - Germany

European ScreeningPort GmbHannounced that it has entered into an agreement with Merck KGaA as part of the New Drugs Fighting neurological diseases Consortium (NEU²). Under the agreement, the European ScreeningPort will use its expertise in order to establish a high-throughput screening assay for a target implicated in multiple sclerosis. This will involve the evaluation of a variety of biochemical and cellular assay formats. Ultimately, it is envisaged that an appropriate high-throughput screening assay can be developed, which can be employed in a small molecule screening campaign to identify starting points for drug discovery. Prof Carsten Claussen, Managing Director comments: "This agreement represents another step forward for the European ScreeningPort being attractive also for the Pharmaceutical industry within new set ups between organizations like us, Academics and the Industry. We will contribute to this project with our expertise and highly flexible approach to challenging projects with the ultimate goal to develop innovative therapies for multiple sclerosis.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances